Skip to main content
SpringerLink
Log in

Multimodality Treatment for Bladder Conservation

  • Reference work entry
  • First Online:
Urologic Oncology

  • 721 Accesses

Abstract

Standard treatment for muscle-invasive urothelial cancer of the bladder is radical cystectomy. Multimodality treatment, including initial transurethral resection of the bladder tumor (TUR-B), followed by concurrent radiochemotherapy (RCT) has been shown to produce survival rates comparable to those of radical cystectomy. With these bladder conservation approaches, (salvage) cystectomy has been reserved for patients with incomplete response or local muscle-invasive relapse. During the past three decades, organ preservation by multimodality treatment has been investigated in prospective series from single centers and cooperative groups, with far more than 1000 patients included. Five-year overall survival rates in the range of 50–60% have been reported, and approximately 80% of the surviving patients maintained their own bladder. Clinical criteria helpful in determining patients for bladder preservation include such variables as small tumor size (<5 cm), early tumor stage, a visibly and microscopically complete transurethral resection, absence of ureteral obstruction, and no evidence of pelvic lymph node metastases. On multivariate analysis, the completeness of TUR-B was found to be one of the strongest predictive factors for overall survival. Patients at greater risk of recurrence after initial complete response are those with multifocal disease and extensive associated carcinoma in situ at presentation. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on optimizing radiation techniques including all possibilities of radiosensitization (e.g., concurrent radiochemotherapy, additional deep regional hyperthermia), and incorporating more effective systemic chemotherapy, and proper selection of patients based on predictive molecular makers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 599.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch : Int J Pathol. 2016;469:339–44.

    Article  CAS  Google Scholar 

  • Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: long-term cumulative results of 2 prospective single-institution studies. Cancer. 2011;117:1190–6.

    Article  CAS  Google Scholar 

  • Choudhury A, Cowan R. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. BJU Int. 2011;108:E313.

    Article  Google Scholar 

  • Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010;70:7017–26.

    Article  CAS  Google Scholar 

  • Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29:733–8.

    Article  Google Scholar 

  • Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270–6.

    Article  Google Scholar 

  • Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14:2901–7.

    Article  CAS  Google Scholar 

  • Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001;165:1111–6.

    Article  CAS  Google Scholar 

  • De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol. 1995;36:183–8.

    Article  Google Scholar 

  • Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys. 1994;30:261–6.

    Article  CAS  Google Scholar 

  • Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61:705–11.

    Article  Google Scholar 

  • Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989;142:1448–53. discussion 53–4

    Article  CAS  Google Scholar 

  • Hata M, Miyanaga N, Tokuuye K, Saida Y, Ohara K, Sugahara S, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys. 2006;64:1371–9.

    Article  Google Scholar 

  • Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006;176:486–92. discussion 91–2

    Article  Google Scholar 

  • Henry AM, Stratford J, McCarthy C, Davies J, Sykes JR, Amer A, et al. X-ray volume imaging in bladder radiotherapy verification. Int J Radiat Oncol Biol Phys. 2006;64:1174–8.

    Article  Google Scholar 

  • Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol). 2007;19:418–26.

    Article  CAS  Google Scholar 

  • Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol. 2005;75:34–43.

    Article  Google Scholar 

  • Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. Journal Clin Oncol: Off J Am Soc Clin Oncol. 2010;28:4912–8.

    Article  Google Scholar 

  • Huddart RA, Jones R, Choudhury A. A new dawn for bladder cancer? Recommendations from the National Institute for Health and Care Excellence (NICE) on Managing Bladder Cancer. Clin Oncol (R Coll Radiol). 2015;27:380–1.

    Article  CAS  Google Scholar 

  • James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88.

    Article  CAS  Google Scholar 

  • Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, et al. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. Int J Cancer. 2015;136:443–51.

    Article  CAS  Google Scholar 

  • Koning CC, Blank LE, Koedooder C, van Os RM, van de Kar M, Jansen E, et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol. 2012;23:2948–53.

    Article  CAS  Google Scholar 

  • Krause FS, Walter B, Ott OJ, Haberle L, Weiss C, Rodel C, et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011;31:985–90.

    PubMed  Google Scholar 

  • Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhoi BP, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int. 2012;110:E1228–36.

    Article  CAS  Google Scholar 

  • Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol. 1991;21:163–70.

    Article  CAS  Google Scholar 

  • Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–6.

    Article  Google Scholar 

  • McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7:418–9.

    Article  Google Scholar 

  • Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, CL W, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14:863–72.

    Article  CAS  Google Scholar 

  • Moyer HR, Delman KA. The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperth. 2008;24:251–61.

    Article  CAS  Google Scholar 

  • Ott OJ, Rodel C, Weiss C, Wittlinger M, St Krause F, Dunst J, et al. Radiochemotherapy for bladder cancer. Clin Oncol (R Coll Radiol). 2009;21:557–65.

    Article  CAS  Google Scholar 

  • Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014a;66:120–37.

    Article  CAS  Google Scholar 

  • Ploussard G, Albrand G, Rozet F, Lang H, Paillaud E, Mongiat-Artus P. Challenging treatment decision-making in older urologic cancer patients. World J Urol. 2014b;32:299–308.

    Article  Google Scholar 

  • Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys. 2005;61:678–86.

    Article  Google Scholar 

  • Pos FJ, Hulshof M, Lebesque J, Lotz H, van Tienhoven G, Moonen L, et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2006;64:862–8.

    Article  Google Scholar 

  • Retz M, Gschwend JE, Maisch P. Short version of the German S3 guideline for bladder cancer. Der Urologe Ausg A. 2016;55:1173–87.

    Article  CAS  Google Scholar 

  • Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–71.

    Article  Google Scholar 

  • Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;40:121–7.

    Article  CAS  Google Scholar 

  • Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176:2414–22. discussion 22

    Article  Google Scholar 

  • Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.

    Article  CAS  Google Scholar 

  • Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457–62.

    Article  Google Scholar 

  • van der Zee J. Heating the patient: a promising approach? Ann Oncol. 2002;13:1173–84.

    Article  Google Scholar 

  • van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet. 2000;355:1119–25.

    Article  Google Scholar 

  • Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 2006;24:2318–24.

    Article  Google Scholar 

  • Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007;68:1072–80.

    Article  CAS  Google Scholar 

  • Weiss C, Sauer R, Rodel C. Radiochemotherapeutic options for bladder cancer. Aktuelle Urol. 2008;39:123–9.

    Article  CAS  Google Scholar 

  • Weiss C, von Romer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, et al. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys. 2009;74:1455–60.

    Article  CAS  Google Scholar 

  • Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–92.

    Article  Google Scholar 

  • Wittlinger M, Rodel CM, Weiss C, Krause SF, Kuhn R, Fietkau R, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93:358–63.

    Article  Google Scholar 

  • Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3:487–97.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Germany

    Oliver J. Ott

Authors
  1. Oliver J. Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver J. Ott .

Editor information

Editors and Affiliations

  1. Department of Urology, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany

    Axel S. Merseburger

  2. Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. der Universität Regensburg, Oberarzt der Klinik für Urologie, Regensburg, Germany

    Wolfgang Otto

  2. Departement of Urology, Weill Cornell Medical Center, New York, NY, USA

    Shahrokh F. Shariat

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ott, O.J. (2019). Multimodality Treatment for Bladder Conservation. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42623-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42623-5_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42622-8

  • Online ISBN: 978-3-319-42623-5

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation